| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6608029 | ASTRAZENECA AB | Methods for regulating gastrointestinal motility |
Sep, 2013
(10 years ago) | |
| US5814600 | ASTRAZENECA AB | Method and composition for treatment of insulin requiring mammals |
Sep, 2015
(8 years ago) | |
| US6114304 | ASTRAZENECA AB | Methods for regulating gastrointestinal motility |
Sep, 2017
(6 years ago) | |
| US5686411 | ASTRAZENECA AB | Amylin agonist peptides and uses therefor |
Mar, 2019
(5 years ago) | |
Symlin is owned by Astrazeneca Ab.
Symlin contains Pramlintide Acetate.
Symlin has a total of 4 drug patents out of which 4 drug patents have expired.
Expired drug patents of Symlin are:
- US6608029
- US5814600
- US6114304
- US5686411
Symlin was authorised for market use on 25 September, 2007.
Symlin is available in injectable;subcutaneous dosage forms.
Symlin can be used as treatment of diabetes with an amylin agonist, including with insulin, treatment of diabetes with an amylin agonist.
The generics of Symlin are possible to be released after 16 March, 2019.
Drugs and Companies using PRAMLINTIDE ACETATE ingredient
Market Authorisation Date: 25 September, 2007
Treatment: Treatment of diabetes with an amylin agonist; Treatment of diabetes with an amylin agonist, including with insulin
Dosage: INJECTABLE;SUBCUTANEOUS
SYMLIN family patents
